Oncotelic Inc.
29397 Agoura Road, Suite 107
Agoura Hills
California
91301
United States
Website: http://oncotelic.com/
42 articles about Oncotelic Inc.
-
Oncotelic Appoints Fatih Uckun, M.D., Ph.D., as Chief Medical Officer
5/3/2022
Oncotelic Therapeutics, Inc., announced the appointment of Dr. Fatih Uckun as its Chief Medical Officer.
-
Oncotelic Provides Ye 2021 Financial Results Compared To Ye 2020, Product Developmet Initiatives And Corporate Update
4/18/2022
OncotelicTherapeutics, Inc. announced financial results for the full year ended December 31, 2021 as compared to the full year ended December 31, 2020, an update on its product and therapeutic development initiatives and other corporate updates.
-
Dr. Anthony E. Maida will be presenting at the Marcus Evans Evolution Summit
3/3/2022
Oncotelic Therapeutics, Inc. and Marcus Evans are proud to announce Dr Anthony E. Maida, Chief Clinical Officer – Translational Medicine for Oncotelic, Inc. as a speaker at the upcoming annual Evolution Summit taking place in Los Angeles this month.
-
Clinical Catch-Up: January 3-7
1/10/2022
The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look. -
ONCOTELIC ANNOUNCES THAT ORF8 MUTATIONS ARE DRIVING THE EVOLUTION OF THE DELTA AND THE OMICRON VARIANTS.
12/22/2021
Oncotelic Therapeutics, Inc. today announced that it has performed mutational analysis of SARS-CoV-2 and demonstrated that the open reading frames 8 (“ORF8”) is potentially driving the evolution of the Delta and the Omicron variants.
-
ONCOTELIC PROVIDES 3RD QUARTER 2021 COMPARED TO 3RD QUARTER 2020 FINANCIAL RESULTS AND CORPORATE UPDATE
11/23/2021
Oncotelic Therapeutics, Inc. today announced financial results for the third quarter ended September 30, 2021 (“ Q3 202 1 ”), as well as an update on its product and therapeutic development initiatives and other corporate updates.
-
ONCOTELIC ANNOUNCES POSITIVE TOPLINE DATA FOR OT-101 C001 COVID STUDY
11/23/2021
Oncotelic Therapeutics, Inc. today announced that its COVID-19 trial (“C001”) for OT-101 has successfully met its safety and efficacy endpoints.
-
Clinical trials have demonstrated that intermittent apomorphine injections provide rapid and effective relief from sudden, unexpected “off” periods brought on by primary Parkinson’s medicine, levodopa.
-
Pulmoheal™/ Artiveda™ Is Clinically Active Against Mild And Moderate Covid-19.
8/24/2021
Oncotelic Therapeutics, Inc., a leading developer of TGF-β therapeutics for oncology and COVID-19, reported that PulmoHealTM/ ArtiVedaTM has proven active against mild and moderate COVID-19 following the preplanned prospective analysis of ARTI-19 clinical trial.
-
ONCOTELIC AND GOLDEN MOUNTAIN PARTNERS FORMING A JOINT VENTURE FOR IPO
8/16/2021
Oncotelic Therapeutics, Inc. and COVID-19 and Golden Mountain Partners, ( “ GMP ” ) announced that they are forming a joint venture ( “JV” ) to advance clinical development of Oncotelic’s pharmaceutical pipeline and build out of manufacturing facilities for the commercial launch of Oncotelic’s drug candidates.
-
Oncotelic Closes Covid-19 Clinical Trial Early.
6/15/2021
Oncotelic Therapeutics, Inc., a leading developer of TGF-β therapeutics for oncology, infectious diseases and respiratory health announced that, as of June 11, 2021, Oncotelic has discontinued enrollment in its OT-101 clinical trial in patients with COVID-19.
-
Oncotelic Joins Chopra Foundation and Heart Foundation of India to Provide Relief for India's Explosive 2nd Wave of Covid.
5/4/2021
Oncotelic Therapeutics, Inc., a leading developer of TGF-β therapeutics for oncology and infectious disease and respiratory health will be working with Chopra Foundation and Heart Care Foundation to provide COVID-19 relief for India, including medicines and oxygen concentrators.
-
ONCOTELIC THERAPEUTICS, INC. ANNOUNCES POSITIVE TOP LINE DATA FOR ARTI-19 CLINICAL TRIAL EVALUATING PULMOHEAL™ VERSUS COVID-19.
4/20/2021
Oncotelic Therapeutics, Inc. (" Oncotelic " or the "Company") (OTCQB:O TLC) , a leading developer of TGF-β therapeutics for oncology and COVID-19, reports positive top line data from its COVID-19 clinical trial, ARTI-19, evaluating PulmoHeal ™ against COVID-19 in India.
-
ONCOTELIC THERAPEUTICS, INC. ANNOUNCES PRESENTATION AT AYURVEDIC PERSPECTIVES ON COVID-19.
3/31/2021
Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC) (f/k/a Mateon Therapeutics, Inc.) announced today that the Chopra Foundation and Jiva are collaborating to bring a webinar regarding new approaches for managing COVID-19 cases as cases spike and new variants arise. The webinar-
-
Mateon is Selected by IBM Watson Health for the Use of IBM Clinical Development Solution at No Cost for Phase II Clinical Trial of OT-101 for COVID-19
6/24/2020
Mateon was approved to use the platform following a review of the program as part of IBM Watson Health’s
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 24, 2020.
-
Mateon Therapeutics Team Publishes Three New Peer-Reviewed Oncology Articles Outlining the Clinical Impact Potential of Its First-In-Class Anti-TGF-Beta RNA Therapeutic OT101/Trabedersen
12/2/2019
Also published was a peer-reviewed research article in the prestigious oncology journal Cancers.
-
New Research Study Provides Target Validation for Mateon’s First-in-Class RNA Therapeutic OT101 for the Treatment of Difficult to Treat Forms of Childhood Brain Tumor
10/23/2019
The article is titled “In silico Molecular Target Validation Demonstrates Transforming Growth Factor Beta 2 is Strongly Expressed in Pediatric Diffuse Intrinsic Pontine Glioma and Glioblastoma Multiforme"
-
WideTrial Partners With Oncotelic to Bring Expanded Access Platform to Cancer
6/3/2019
WideTrial Inc., a third-party sponsor of Expanded Access programs, has begun a partnership with Oncotelic Inc., a wholly owned subsidiary of Mateon Therapeutics Inc., to provide OT-101 to patients who cannot take part in research trials of the investigational product.
-
MabVax Therapeutics and Oncotelic Enter into Merger Discussions
1/4/2019
Divestiture of Selected MabVax Assets Managed by Objective Capital Will Continue